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Objectives: SS-cream is a topical agent made from the extracts of natural products for treating
premature ejaculation (PE). To determine the optimal clinical dosage of SS-cream on PE, we
investigated the safety and efficacy of SS-cream with various doses. A double blind, randomized
placebo controlled clinical study was performed.
Methods: Fifty patients completed the study. Mean age of the patients was 37.1 1.0 y and mean
ejaculatory latency was 1.35 0.07 min. Sexual satisfaction rate of both the partner and patient was
16.2%. Each patient was instructed to apply the different cream (placebo, SS-cream 0.05, 0.10,
0.15, 0.20 g) on glans penis 1 h before sexual intercourse in random fashion. The ejaculatory
latency was measured by stop watch and the satisfaction rate of both partner and patient was also
recorded two times in the screening period and after the application of each test drugs. Clinical
efficacy was considered if ejaculatory latency was prolonged more than 2 min and sexual
satisfaction rate increased more than 20% than that of pretest values.
Results: The mean ejaculatory latencies were significantly prolonged after using various test drugs
(placebo 2.27 0.32, SS-cream 0.05 g 4.47 0.81, 0.10 g 5.34 0.79, 0.15 g 6.22 0.87, 0.20 g
11.06 1.17 min, respectively). Clinical efficacies evaluated by ejaculatory latency were placebo
18%, SS-cream 0.05 g 30%, 0.10 g 60%, 0.15 g 54%, 0.20 g 84%, respectively. The satisfaction rate
was also significantly increased dose-dependently (placebo 26%, SS-cream 0.05 g 60%, 0.10 g
70%, 0.15 g 78%, 0.20 g 90%, respectively). A side effect such as local mild burning sensation was
noted in 35/250 times (14%) and no adverse effect on sexual function and no systemic side effects
were observed. From the result of logistic regression analysis on clinical efficacy, the ED50 of SS-
cream was obtained as 0.10 g. SS-cream 0.20 g was effective in 84% without any serious systemic
side effects.
Conclusion: From the above results, our conclusions are that SS-cream is effective on the treatment
of PE with a few local side effects and that clinical optimal dose of SS-cream is 0.20 g.
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Introduction
Premature ejaculation (PE) is the most common type
of male sexual dysfunction and defined as the
absence of voluntary control over the ejaculation
resulting ejaculation either precedes vaginal entry or
occurs immediately upon vaginal entry.1,2 The cause
of PE has been thought to be psychological in the
majority of patients and little is known about its
organic basis.3–5 Therefore, the management of PE
rests primarily on sex therapy and counseling. The
expanded ‘squeeze technique’ and ‘stop-start tech-
nique’ is also attempted to increase the pre-ejacula-
tory period. However, these therapies require the
active participation of both partners and is hard for
the patients to follow the techniques. In our
experience such therapies have been dismal in
successfully treating the male patient with PE.
Other treatments and approaches have been tried
and suggested. Pharmacological treatment has been
attempted with neuroleptics, antidepressants, a-
blockers, lorazepam, clomipramine but this ap-
proach is not entirely successful and is associated
with various adverse effects.6–10 Other treatments
for PE, such as topical application, neurotomy, and
intracavernosal medication have been reported.11–13
As for the treatment of PE, every currently available
method has its limitations and side effects.
Our studies of penile biothesiometry and penile
somatosensory evoked potential (SEP) in patients
with PE showed the vibration threshold in patients
with primary PE was significantly lower than that of
normal men and the latency SEP was reduced and
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amplitude of SEP was increased those of normal
men.14–16 It can be suggested that the penile
hypersensitivity and/or hyperexcitability may be
the organic basis of PE. Therefore, we hypothesized
that decreasing the penile hypersensitivity will be
an effective treatment against PE.
SS-cream is a topical agent for treatment of PE
which was made with carefully selected extracts of
nine natural products (Ginseng Radix alba, Angel-
icae gigantis Radix, Cistanchis Herba, Torilidis
Semen, Caryophylli Flos, Cinnamoni Cortex,
Zanthoxyli Fructus, Asiasari Radix and Bufonis
Veneum), which is based on the traditional herb
remedy and the action mechanisms of SS-cream are
believed to have local desensitizing effects and
enhancing capabilities of the local blood flow and
was effective in the treatment of PE in the pilot,
clinical studies.18,19 The composition of the cream
is: 70% extract of Bufonis Veneum, 10 mg; Ginseng
Radix Alba fructose, 100 mg; extract of Asiasari
Radix, Carophylli Flos, Cinnamoni Cortex, 10 mg. In
order to evaluate clinical efficacy and safety of SS-
cream to determine clinical optimal dose of SS-
cream, a double blind, randomized, placebo con-
trolled clinical study was performed with various
doses of SS-cream.
Materials and methods
Seventy-three patients with primary PE visiting the
Department of Urology, Yongdong Severance Hos-
pital who agreed to participate in the clinical study
and signed an informed consent enrolled in our
study from January 1997 to June 1997. Subjects
included patients with primary PE only who
complained of PE from their beginning of their
sexual life and married and heterosexual with stable
partner. The ejaculatory latencies of patients were
less than 3 min and/or sexual satisfaction rate were
less than 50%. In all patients, physical examina-
tions, including genitalia were normal and complete
blood profile, liver and renal function test, testoster-
one, and prolactin were also without abnormalities.
Patients with secondary PE and PE combined with
erectile dysfunction, genitourinary tract infection
such as prostatitis, urethritis and epididymitis,
neurological disorders, and obvious psychological
problems requiring psychiatric support and admin-
istration of any anti-depressants that might alter
sexual activities were excluded. Patients where the
ejaculatory latency time was longer than 3 min and/
or sexual satisfaction rate was more than 50% were
excluded from study.
Test drugs included SS-cream 0.05 g, 0.10 g 0.15 g,
0.20 g and placebo which was made with cream base
of thesamecolor andsmell of SS-cream.Each test drug
packaged and labelled in the same manner. They were
given a code randomly according to allocation table
and the information about the test drug was kept by
the controller and provided at the time of data
analysis.
All subjects were instructed to apply the cream
on the glans penis 1 h before sexual intercourse and
wash it off before sexual intercourse and asked to
measure the ejaculatory latency from vaginal intro-
mission to ejaculation with a stop-watch. The degree
of satisfaction of both the patient and their partners
were recorded and they were asked to complete the
report form that included the occurrence of side
effects.
Clinical efficacies were interpreted as if ejacula-
tory latency was prolonged more than 2 min and the
sexual satisfaction rate was increased more than
20% over the screening period.
Statistical analysis was performed using paired
Student’s t-test, ANOVA and multiple comparison
test, and w2-test for differences between test drugs.
The logistic regression analysis was used to find the
dose relation of SS-cream. Values represented in
mean standard error and P-value less than 0.05
was regarded as having statistical significance.
Results
Seventy-three patients were enrolled in this study
and 50 completed the entire study and mean age of
patients was 37.1 0.96 y and mean ejaculatory
latency time was 1.35 0.07 min and sexual satis-
faction rate of both the partner and patient was
16.2%. Twenty-three patients dropped out (lost
during follow up 18, incorrect code recording 3,
marital/partner problem 2).
After the application of each test drugs ejacula-
tory latencies were significantly prolonged (placebo
2.27 0.32, SS-cream 0.05 g 4.47 0.81, SS-cream
0.10 g 5.34 0.79, SS-cream 0.15 g 6.22 0.87, SS-
cream 0.2 g 11.06 1.17 min) (Figure 1).
Clinical efficacies evaluated by ejaculatory laten-
cy were placebo 18%, SS-cream 0.05 g 30%, SS-cream
Figure 1 Ejaculatory latencies of before and after application of
different doses of SS-cream on the glans penis in patients with
primary premature ejaculation. The ejaculatory latencies were
significantly prolonged as dose increased (P<0.001).
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0.10 g 60%, SS-cream 0.15 g 54%, SS-cream 0.20 g
84%, respectively (Figure 2).
Satisfaction rate before treatment was
16.2 13.5% and after the application of different
test drugs were: placebo 26%, SS-cream 0.05 g 60%,
SS-cream 0.10 g 70%, SS-cream 0.15 g 78%, SS-
cream 0.20 g 90%, respectively (Figure 3).
Thirty-seven of 250 (14.8%) test trials of SS-
cream have been associated with mild local burning
sensations (placebo 4, SS-cream 0.05 g 7, 0.10 g 9,
0.15 g 7, 0.20 g 10 respectively) and one (0.04%)
complained of mild penile pain. The occurrence of
side effects tended to increase according to increase
in dosage, but no statistical importance was ob-
served. Systemic or other local minor side effects
were not noted and no adverse effects on sexual
function and on partners were observed.
According to the result of logistic regression
analysis, ED50 of SS-cream was 0.10 g. In the result
of clinical optimal dose (0.2 g) of SS-cream showed
efficacy of 84%, and no significant increase in
side effect was noted compared to ED50 (0.10 g)
(Figure 4).
Discussion
Human sexual function includes sexual libido,
penile erection, ejaculation and orgasm. Ejaculation
is related to immediate sequential reflex mechan-
isms. One of the apparent functions of the afferent
fibers of penile innervation is to provide the cerebral
sensory cortex with appropriate information to
promote the efferent stimulation of the pelvic-
cavernous pathway. Premature ejaculation is the
most common type of sexual dysfunction of uncon-
trolled ejaculatory reflex. Causes of PE may be a
psychologic disorder and somatic basis of penile
hypersensitivity and/or hyperexcitability.
Patients with PE can be divided into primary and
secondary PE. Primary PE patients were those who
had suffered chronically since the beginning of their
sexual lives and secondary PE patients were those
who suffered from PE after years of normal sexual
functioning. In our study we evaluated only patients
with primary PE because other conditions, which
have been implicated with PE but not clearly proven
to be etiologic, were excluded.
In this study we investigated ejaculatory latency
from vaginal entry of penis to ejaculation and
investigated satisfaction and clinical efficacy con-
sidered as ejaculatory latency prolonged more than
2 min and satisfaction rate increased more than 20%
Figure 2 Clinical efficacies according to different doses of SS-
cream in patients with primary premature ejaculation. The
clinical efficacies were 18% in placebo, 30% in 0.05 g, 60% in
0.10 g, 54% in 0.15 g and 84% in 0.20 g of SS-cream. **Clinical
efficacies were calculated by the ejaculatory latency prolonged
more than 2 min after the application of the cream on glans penis.
Figure 4 Dose–response curve of the clinical efficacy of SS-
cream evaluated by the ejaculatory latency and the satisfaction
degree. The clinical efficacy of SS-cream increased as dose
increased (P< 0.001).
Figure 3 Satisfaction degree according to different doses of SS-
cream and placebo in patients with primary premature ejacula-
tion. The satisfaction degrees were significantly increased as
doses of SS-cream were increased (P<0.001).
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over that of screening period. Even so, the clinical
efficacy of SS-cream showed dose dependently
increased to 84% evaluated by ejaculatory latency
and 90% evaluated by satisfaction rate.
The ideal management modality of PE should be
simple with maximal effects with little side effects.
A topical agent that desensitizes the penile hyper-
sensitivity, restores the normal ejaculatory reflex
and also enhances the penile erection, with no
adverse effects on the individual’s orgasm or upon
the partners, can be the ideal drug.
SS-cream is a topical agent for treatment of PE
which was made with carefully selected extracts of
nine natural products (Ginseng Radix alba, Angel-
icae gigantis Radix, Cistanchis Herba, Torilidis
Semen, Caryophylli Flos, Cinnamoni Cortex,
Zanthoxyli Fructus, Asiasari Radix and Bufonis
Veneum) and is taken as mixture for a particular
ailment so the interaction or synergy is far more
significant than the specific reaction of each in-
dividual drug. Therefore SS-cream may work natu-
rally and completely to restore physical well being
for treating PE.
An animal study showed that SS-cream had
almost no toxicity (LD50 9.3 g/kg) and no histolo-
gical changes after the long term topical application
of SS-cream on the glans penis, cornea and skin of
rabbits and rats. SS-cream inhibited pin-prick
induced corneal reflex of rabbit dose dependently
and prolonged the latency of SEP and reduced
amplitude of SEP stimulated glans penis of rabbit.
Some components of SS-cream, such as eugenol
from Caryophylli Flos, bufotalin from Bufonis
Veneum and methyl leugenol from Asiasari Radix,
have local desensitizing effects. SS-cream also
showed the relaxation effect on rabbit corpus
cavernosal muscles in a dose dependent manner.18
The main pharmacological action of SS-cream on
the treatment of PE is believed to be in decreasing
the penile hypersensitivity to a normal level for
restoring the ejaculatory reflex arc and in enhancing
the penile blood flow due to combined activity of
vasoactive principles.
In this study the side effect of SS-cream was mild
local burning sensation in 39 of 250 trials (14.8%:
placebo 7, SS-cream 0.05 g 8, 0.10 g 9, 0.15 g 12,
0.20 g 10) and mild pain 0.04%. The occurrence of
side effects tended to increase according to the
increase of dosage, but no statistical importance was
observed. Systemic or other local minor side effects
were not noted and no adverse effect on sexual
function and on partner was observed.
Conclusions
With these results, we can conclude that SS-cream
is effective and safe in the treatment of PE. In the
result of logistic regression analysis on clinical
efficacy, the ED50 of SS-cream was 0.10 g. As the
clinical efficacy of SS-cream ranged from 0.05 g to
0.20 g with no significant increase in side effects
compared to ED50 (SS-cream 0.10 g), SS-cream 0.20 g
was determined as the clinical optimal dose.
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